Clinical Study of PD-1 Monoclonal Antibody SHR-1210 Combined With Epirubicin in the Treatment of Extensive Small Cell Lung Cancer After First-line Treatment Failure
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Epirubicin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 15 Jan 2019 Planned primary completion date changed from 28 Apr 2019 to 28 Oct 2019.
- 15 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 04 Dec 2018 New trial record